Patents Examined by Svetlana M Ivanova
  • CNS pharmaceutical compositions and methods of use
    Patent number: 9579299
    Abstract: The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy/activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and/or released.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: February 28, 2017
    Assignee: Targia Pharmaceuticals
    Inventor: Sabina Glozman
  • Formulations of bendamustine
    Patent number: 9572887
    Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: February 21, 2017
    Assignee: EAGLE PHARMACEUTICALS, INC.
    Inventor: Srikanth Sundaram
  • Formulations of bendamustine
    Patent number: 9572888
    Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: February 21, 2017
    Assignee: EAGLE PHARMACEUTICALS, INC.
    Inventor: Srikanth Sundaram
  • Dosing regimen for sedation with CNS 7056 (Remimazolam)
    Patent number: 9561236
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: February 7, 2017
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Kinase modulation and indications therefor
    Patent number: 9550768
    Abstract: Compounds, compositions and methods useful for treatment of Flt3-mediated diseases or conditions are provided herewith. Also provided herewith are methods for modulating the receptor protein tyrosine like kinase 3(Flt3).
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 24, 2017
    Assignee: Plexxikon Inc.
    Inventors: Chao Zhang, Gideon Bollag, Gaston Habets, Jiazhong Zhang, Prabha N. Ibrahim, Guoxian Wu
  • Muscarinic agonists as enhancers of cognitive flexibility
    Patent number: 9549928
    Abstract: Methods and compositions for treating a mental condition in a subject in need thereof, includes administering to a subject in need thereof an effective amount of a CDD-102A compound [5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine], or a pharmaceutically acceptable salt or hydrate thereof pharmaceutically acceptable salt or hydrate thereof.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: January 24, 2017
    Assignees: THE UNIVERSITY OF TOLEDO, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: William S. Messer, Michael Ragozzino
  • Biocidal composition of 2,6-dimethyl-m-dioxane-4-ol acetate and methods of use
    Patent number: 9526249
    Abstract: Provided is a biocidal composition comprising 2,6-dimethyl-m-dioxane-4-ol acetate and an isothiazolinone biocidal compound. The composition is useful for controlling microorganisms in aqueous or water containing systems.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: December 27, 2016
    Assignee: DOW GLOBAL TECHNOLOGIES LLC
    Inventors: Ioana Annis, Jon B. Raymond, Emerentiana Sianawati
  • Biocidal composition of 2,6-dimethyl-m-dioxane-4-ol acetate and methods of use
    Patent number: 9521849
    Abstract: Provided is a biocidal composition comprising 2,6-dimethyl-m-dioxane-4-ol acetate and an isothiazolinone biocidal compound. The composition is useful for controlling microorganisms in aqueous or water containing systems.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: December 20, 2016
    Assignee: DOW GLOBAL TECHNOLOGIES LLC
    Inventors: Ioana Annis, Jon B. Raymond, Emerentiana Sianawati
  • and cancer
    Patent number: 9511080
    Abstract: The present invention provides compositions, methods of manufacture, process and uses for diagnosing, preventing, inhibiting, and treating the development and proliferation of diseases and disorders associated with Okadaella gastrococcus (Og) bacterial infection in a patient.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: December 6, 2016
    Assignee: Okada Medical Services Pty Ltd
    Inventor: Takayuki Okada
  • 1-aminocyclohexane derivatives for the treatment of cochlear tinnitus
    Patent number: 9498450
    Abstract: The present invention relates to the treatment of an individual afflicted with cochlear tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: November 22, 2016
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Barbara Ellers-Lenz, Tanja Rosenberg, Hagen Kruger, Michael Althaus
  • Compositions for treating cognitive disorders
    Patent number: 9492543
    Abstract: Disclosed herein is a pharmaceutical composition comprising a cholinesterase inhibitor and compound of the following formula: The composition is effective for treating cognitive disorders, and methods of treating such disorders using the composition are also disclosed.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: November 15, 2016
    Assignee: Allergan, Inc.
    Inventors: Ursula V. Staubli, John E. Donello
  • Pesticidal compositions
    Patent number: 9462808
    Abstract: A pesticidal composition comprising a pesticidal effective amount of at least one compound of formula (I) in which the substituents are as defined as in claim 1, and a safener.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: October 11, 2016
    Assignee: Syngenta Participants AG
    Inventors: Anke Buchholz, Christoph Grimm
  • Methods and compositions for preventing and treating auditory dysfunctions
    Patent number: 9457009
    Abstract: The invention provides methods for treating auditory impairments in a subject in need of treatment comprising administering to said subject an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester, a quinic acid derivative, a caffeic acid derivative, a ferulic acid derivative, or a quinic acid lactone or derivative thereof or pharmaceutically acceptable salt thereof and an acceptable carrier or excipient, so as to treat auditory impairments in the subject.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: October 4, 2016
    Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventor: O'neil W. Guthrie
  • Form of administration of enkephalinase inhibitor
    Patent number: 9439853
    Abstract: The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhea.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: September 13, 2016
    Assignee: BIOPROJET
    Inventors: Jean-Stëphane Julien, Marc Maury, Jeanne-Marie Lecomte, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • Methods for reducing uric acid levels using barbiturate derivatives
    Patent number: 9428466
    Abstract: Methods for reducing uric acid levels in blood or serum of a subject employing metabolites of merbarone as active agents. Methods for treating or preventing disorders of uric acid metabolism are also provided. The metabolites can be formulated as pharmaceutical compositions comprising the metabolites and a pharmaceutically acceptable carrier for use in these methods.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: August 30, 2016
    Inventor: Raymond P. Warrell, Jr.
  • Compositions comprising amino acids for prevention and/or treatment of renal disorders
    Patent number: 9421190
    Abstract: Composition comprising leucine, isoleucine, valine, threonine and lysine for use in prophylactic and/or therapeutic treatment of renal disorders in a subject, preferably an elderly subject.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: August 23, 2016
    Assignee: DETERMINANTS OF METABOLISM RESEARCH LABORATORY S.R.L.
    Inventors: Franco Conti, Francesco Saverio Dioguardi
  • Compositions comprising terpene compounds for treating negative sensory phenomena
    Patent number: 9415023
    Abstract: Compositions comprising terpene compounds for the treatment of negative sensory phenomena (NSP). Negative sensory phenomena is characterized by a decreased ability to sense light touch, pin prick, vibration, temperature, pain and/or reduced proprioception. The terpene compounds are preferably aromatic terpene compounds such as geraniol and citronellol and analogs thereof. The terpenes may also be used in combination. The terpenes are derived form plant essential oils or are manufactured synthetically.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: August 16, 2016
    Assignees: NeuroQuest Inc., Board Of Supervisors Of Louisana State University And Agricultural And Mechanical College Pennington Biomedical Research Center
    Inventors: Alexander McLellan, Frank Greenway
  • Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation
    Patent number: 9364448
    Abstract: A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione), also known as NTBC for a sufficient period of time. The administration of NTBC is believed to increase the amount of pigmentation in the subject and alleviate certain symptoms caused by lack of pigmentation in the eye tissues. Also described are methods of use of NTBC for increasing the pigmentation of a subject for cosmetic purposes, by administering to the subject a therapeutically effective amount of NTBC.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: June 14, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Brian P. Brooks, William A. Gahl
  • Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
    Patent number: 9359313
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: June 7, 2016
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Maria Carmen Valcarce Lopez
  • Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
    Patent number: 9358236
    Abstract: The present invention relates to a combination of an allosteric mTOR inhibitor and a catalytic mTOR inhibitor for use in the prevention or treatment of neurodegenerative diseases, for example Huntington's Disease, and products and pharmaceutical compositions comprising such a combination for use in the prevention or treatment of such neurodegenerative diseases.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: June 7, 2016
    Assignee: Novartis AG
    Inventors: Leon Murphy, Jvan Galimberti